ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 380,74
0,92%
Dow Jones
42 544,22
-0,07%
DAX
19 909,14
-0,25%
Brent Oil
74,85
0,00%
Bitcoin
93 325,09
-0,06%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Edgewise Therapeutics Inc (EWTX) Cours

Edgewise Therapeutics Inc

Edgewise Therapeutics Inc (EWTX)

NASDAQ
26,70
-0,355
(-1,31%)
À la fermeture: 01 Janvier 10:00PM
Retardé de 15 minutes
26,70
0,03
( 0,11% )
Après les heures de négociation: 11:30PM
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
26,70
Prix Achat
26,00
Prix Vente
28,56
Volume échangé
709 951
25,97 Fourchette du Jour 27,92
9,00 Plage de 52 semaines 38,12
Cap du marché
2,528B
Clôture Veille
27,055
Ouverture
27,12
Dernière Transaction
1
@
26.32
Dernière heure de transaction
22:40:58
Volume financier
US$ 18 814 656
VWAP
26,5013
Volume moyen (3 m)
833 482
Actions en circulation
94 688 517
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-25,21
Bénéfice par action (BPA)
-1,06
Chiffre d'affairess
-
Bénéfice net
-100,16M

À propos de Edgewise Therapeutics Inc

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.edgewisetx.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Edgewise Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker EWTX. Le dernier cours de clôture d'Edgewise Therapeutics était de US$27,06. Au cours de la dernière année, les actions de Edgewise Therapeutics ont été négociées dans une fourchette de prix de US$ 9,00 à US$ 38,12.

Edgewise Therapeutics compte actuellement 94 688 517 actions en circulation. La capitalisation boursière d'Edgewise Therapeutics est de US$2,56 milliard. Edgewise Therapeutics a un ratio cours/bénéfice (ratio PE) de -25.21.

EWTX Dernières nouvelles

Plus de nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

il y a 2 heures
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

30 Décembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

16 Décembre 2024
Edgar (US Regulatory)

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

– Trial met primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to date – –...

16 Décembre 2024
Business Wire

Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided information regarding the company’s relationship with Dr. Han Phan at Rare Disease...

05 Décembre 2024
Business Wire

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare...

26 Novembre 2024
Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans

07 Novembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Novembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 Novembre 2024
Edgar (US Regulatory)

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– On track to announce top-line results from Phase 2 CANYON trial of sevasemten in adults with Becker in December 2024 – – Advanced Phase 2 LYNX and FOX trials of sevasemten in children and...

07 Novembre 2024
Business Wire
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-3.36-11.177644710630.0630.22526.6750695428.55167674CS
4-4.62-14.750957854431.3235.526.6793434630.69611976CS
12-0.95-3.4358047016327.6538.1226.6783348232.38228836CS
268.7148.415786548117.9938.1214.7599264826.14167281CS
5215.77144.2817932310.9338.12991454721.68318493CS
15612.0482.128240109114.6638.125.1247941117.29096765CS
260-0.3-1.111111111112740.495.1241956717.72331538CS

EWTX - Frequently Asked Questions (FAQ)

What is the current Edgewise Therapeutics share price?
The current share price of Edgewise Therapeutics is US$ 26,70
How many Edgewise Therapeutics shares are in issue?
Edgewise Therapeutics has 94 688 517 shares in issue
What is the market cap of Edgewise Therapeutics?
The market capitalisation of Edgewise Therapeutics is USD 2,56B
What is the 1 year trading range for Edgewise Therapeutics share price?
Edgewise Therapeutics has traded in the range of US$ 9,00 to US$ 38,12 during the past year
What is the PE ratio of Edgewise Therapeutics?
The price to earnings ratio of Edgewise Therapeutics is -25,21
What is the reporting currency for Edgewise Therapeutics?
Edgewise Therapeutics reports financial results in USD
What is the latest annual profit for Edgewise Therapeutics?
The latest annual profit of Edgewise Therapeutics is USD -100,16M
What is the registered address of Edgewise Therapeutics?
The registered address for Edgewise Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Edgewise Therapeutics website address?
The website address for Edgewise Therapeutics is www.edgewisetx.com
Which industry sector does Edgewise Therapeutics operate in?
Edgewise Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
TOIIWOncology Institute Inc
US$ 0,0098
(88,46%)
4,37k
AEIAlset Inc
US$ 1,68
(64,71%)
607,41k
CMCTCreative Media and Community Trust Corporation
US$ 0,3625
(61,11%)
16,8M
VSMEVS Media Holdings Ltd
US$ 2,09
(60,77%)
433,84k
PASGPassage Bio Inc
US$ 0,725
(27,84%)
452,77k
BDMDBaird Medical Investment Holdings Ltd
US$ 4,97
(-34,61%)
1,84M
AILEiLearningEngines Inc
US$ 0,3106
(-26,05%)
1,13M
MARXMars Acquisition Corporation
US$ 7,20
(-22,99%)
9,77k
HUBCWHub Cyber Security Ltd
US$ 0,03
(-20,11%)
2,5k
CETYClean Energy Technologies Inc
US$ 0,50
(-18,51%)
58,38k
CMCTCreative Media and Community Trust Corporation
US$ 0,3625
(61,11%)
16,8M
XTIAXTI Aerospace Inc
US$ 0,0412
(-4,19%)
8,07M
CRKNCrown Electrokinetics Corporation
US$ 0,145
(1,97%)
6,8M
EYENEyenovia Inc
US$ 0,1324
(-9,32%)
4,88M
SVMHSRIVARU Holding Ltd
US$ 0,0449
(6,65%)
4,05M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
EWTX
Edgewise Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés